Academic literature on the topic 'Pharmacomodulations'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacomodulations.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmacomodulations"
Marc, Sylvain, Christophe Mésangeau, Mathilde Coevoet, Amélie Barczyk, Stéphane Burlet, Philippe Verwaerde, Cecilia Estrella, et al. "Pharmacomodulations around an anti-Alzheimer drug-candidate." European Journal of Medicinal Chemistry Reports 4 (April 2022): 100020. http://dx.doi.org/10.1016/j.ejmcr.2021.100020.
Full textLogé, Cédric, Valérie Wallez, Elizabeth Scalbert, Christelle Cario-Tourmaniantz, Gervaise Loirand, Pierre Pacaud, and Daniel Lesieur. "Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885." Journal of Enzyme Inhibition and Medicinal Chemistry 17, no. 6 (January 1, 2002): 381–90. http://dx.doi.org/10.1080/1475636021000005659.
Full textMessire, Gatien, Patrick Rollin, Isabelle Gillaizeau, and Sabine Berteina-Raboin. "Synthetic Modifications of Andrographolide Targeting New Potential Anticancer Drug Candidates: A Comprehensive Overview." Molecules 29, no. 12 (June 18, 2024): 2884. http://dx.doi.org/10.3390/molecules29122884.
Full textLogé, Cédric, Xavier Siomboing, Valérie Wallez, Elizabeth Scalbert, Caroline Bennejean, Christelle Cario-Tourmaniantz, Gervaise Loirand, Bernard Gressier, Pierre Pacaud, and Michel Luyckx. "Synthesis and Pharmacological Study of Rho-Kinase Inhibitors: Pharmacomodulations on the Lead Compound Fasudil." Journal of Enzyme Inhibition and Medicinal Chemistry 18, no. 2 (April 1, 2003): 127–38. http://dx.doi.org/10.1080/1475636031000093561.
Full textAmeryckx, Alice, Lionel Pochet, Gang Wang, Esra Yildiz, Bouazza Es Saadi, Johan Wouters, Françoise Van Bambeke, and Raphaël Frédérick. "Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio." European Journal of Medicinal Chemistry 200 (August 2020): 112444. http://dx.doi.org/10.1016/j.ejmech.2020.112444.
Full textStern, Eric, Giulio G. Muccioli, Barbara Bosier, Laurie Hamtiaux, Régis Millet, Jacques H. Poupaert, Jean-Pierre Hénichart, Patrick Depreux, Jean-François Goossens, and Didier M. Lambert. "Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality." Journal of Medicinal Chemistry 50, no. 22 (November 2007): 5471–84. http://dx.doi.org/10.1021/jm070387h.
Full textMustière, Romain, Prisca Lagardère, Sébastien Hutter, Céline Deraeve, Florian Schwalen, Dyhia Amrane, Nicolas Masurier, et al. "Pd-catalyzed C–C and C–N cross-coupling reactions in 2-aminothieno[3,2-d]pyrimidin-4(3H)-one series for antiplasmodial pharmacomodulation." RSC Advances 12, no. 31 (2022): 20004–21. http://dx.doi.org/10.1039/d2ra01687g.
Full textMouysset, Geneviève, Marc Payard, Gérard Grassy, Pierre Tronche, Hubert Dabire, Paule Mouille, and Henri Schmitt. "Pharmacomodulation d'adrénolytiques aα en série benzopyrannique." European Journal of Medicinal Chemistry 22, no. 6 (November 1987): 539–44. http://dx.doi.org/10.1016/0223-5234(87)90294-7.
Full textVarache-Béranger, Martine, Alain Nuhrich, and Guy Devaux. "Pharmacomodulation d'arylcétones thiophéniques anti-agrégantes plaquettaires." European Journal of Medicinal Chemistry 23, no. 6 (November 1988): 501–10. http://dx.doi.org/10.1016/0223-5234(88)90092-x.
Full textRenault, Jacques, Aurelie Bernard, Solenn Brajeul, Pierre Verhaeghe, Sabrina Butt, Frederic Fabis, François Dauphin, Philippe Uriac, and Sylvain Rault. "Pharmacomodulation of a Sulfamide 5-HT6 Receptor Ligand." Journal of Enzyme Inhibition and Medicinal Chemistry 19, no. 6 (December 1, 2004): 577–83. http://dx.doi.org/10.1080/14756360400004540.
Full textDissertations / Theses on the topic "Pharmacomodulations"
Dumonteil, Geoffrey. "Synthèse et pharmacomodulations de composés naturels issus de plantes." Thesis, Orléans, 2015. http://www.theses.fr/2015ORLE2061/document.
Full textPolyene units constitute an important function from organic compounds and are present in many natural products in the form of 1,3-conjugated dienes. It is therefore essential to develop methods to access these dienes while wearing a careful look at the environmental impact. During this work, we were able to synthesize a natural compound which has activity on type II diabetes: the abscisic acid. The key step leading to the success of this synthesis is the Heck reaction. From these results, we have developed a robust and efficient method to obtain various diene compounds (E, Z) and trienes (E, E, Z) without ligand or solvent. The compounds thus obtained are considered as potential analogues of the abscisic acid and are involved in various reactions in order to obtain the corresponding carboxylic acid or its bioisostere. In parallel with this synthesis application, we have developed a pathway to obtain benzo[d]thiazole compounds substituted in position 2 with an N-aryl or N-alkyl. This synthetic methodology is part of a context of environmental compatibility by using iodine catalyst
Perri, Vittoria. "Synthèse, pharmacomodulations et évaluation biologique de « tripentones » à visée anticancéreuse." Caen, 2010. http://www.theses.fr/2010CAEN4001.
Full textThe work described in this document deals with the synthesis, the physico-chemical study and the biological evaluation of new 3-aryl-8H-thieno[2,3-b]pyrrolizin-8-ones, the “Tripentones”. The discovery of this new family of compounds derives from many research programs developed at the “Centre d’Etude et de Recherche sur le Médicament de Normandie”. Following a description of different classes of kinases and their inhibitors, previous works carried out in our laboratory about the tripentones are reviewed. The main subject of this thesis concerns the pharmacomodulation of the hit compound of this family called MR 22388. The synthesis are followed by the description of pharmacological results obtained by our compounds on biological targets in the field of oncology. This work also opens up new prospects for pharmacomodulation of the tripentones and the development of new methodologies of synthesis. Lastly, the experimental part of this document describes the chemical structures, the procedures and the physicochemical properties of all the presented compounds. Finally, the bibliography comprises more than 150 references
LE, GOFF-BEVIERE CORINNE. "Pharmacomodulations de quinolones a structure benzo-ij-quinolizine : synthese et activite antibacterienne." Orléans, 1995. http://www.theses.fr/1995ORLE2019.
Full textGrisel, Clément. "Conception de cyclopeptides antiviraux inspirés d'un produit naturel." Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASQ055.
Full textAccording to the WHO, arboviruses such as Zika virus, dengue, and chikungunya represent a major public health challenge, frequently causing outbreaks with sometimes severe symptoms. In collaboration with the PIMIT laboratory, we performed a screening of the ICSN plant extract library, leading to the discovery of a new family of cyclopeptides with potent antiviral properties. To identify an orally bioavailable candidate for in vivo trials, I first developed an efficient synthetic route to access these types of compounds. The preparation of two non-canonical amino acids was initially developed before completing the total synthesis of two natural molecules via SPPS. Building on this synthetic strategy, we then created a library of 36 analogs by modifying four positions on the lead natural cyclopeptide. The antiviral activity results highlighted strong structure-activity relationship (SAR) data, complemented by pharmacokinetic studies. These findings guided us in selecting key amino acids for designing new orally bioavailable antiviral cyclopeptides derived from nature
Dardenne, Jérémy. "Premières pharmacomodulations de la meiogynine A, un sesquiterpène dimère inhibiteur de l'interaction Bcl-xL/Bak, régulant l'apoptose." Phd thesis, Université Paris Sud - Paris XI, 2012. http://tel.archives-ouvertes.fr/tel-00774836.
Full textVidaillac, Céline. "Pharmacomodulations en série pyrrolo[1,2-a]quinoxaline : application à la mise au point d'inhibiteurs de pompes d'efflux." Bordeaux 2, 2007. http://www.theses.fr/2007BOR21439.
Full textEfflux systems are transmembrane transporters, involved in antibiotic and anticancer resistances. The discovery of efflux pump inhibitors (EPIs) is an essential way of research in chemotherapy. The aim of this thesis was to synthesize and evaluate the in vitro activity of new EPIs. Three series of pyrrolo [1,2a]quinoxaline molecules have been elaborated on the basis of structural criteria of reference EPIs (omeprazole, quinoline derivatives and INF), and have been assessed as inhibitors of bacterial efflux systems. A strategy of evaluation has been defined using NorA of Staphylococcus aureus, which is considered as the prototype of Gram positive MDR (MultiDrug Resistance) systems. This strategy included screening tests, evidence of EPI-antibiotic synergy, and investigation of the inhibition lechanism. Among each series, several molecules were more active than reference EPIs. Preliminary structure-activity relationship studies highlighted the influence of particular chemical elements (heterocycle, sulphur atom, protonable functions) on the EPI activity. Some molecules (1e, 11g, 11m and 17) might provide the basis for further pharmacomodulation to obtain therapeutically useful drugs. However, the third series, compared to 8 reference EPIs on 10 efflux systems representative of the 5 classes of transporters, has confirmed that the hypothesis of a very wide-spectrum EPI is unlikely. Finally, two other series of pyrrolo [1,2-a] quinoxaline molecules have been designed on the basis of the chemical structures of MS-073 and MS-207 and pyrrolopyrimidine derivatives, in order to broaden the biological application to cancerology
Dardenne, Jérémy. "Premières pharmacomodulations de la meiogynine A, un sesquiterpène dimère inhibiteur de l’interaction Bcl-xL/Bak, régulant l’apoptose." Thesis, Paris 11, 2012. http://www.theses.fr/2012PA114852/document.
Full textThe control of the apoptosis is one of the new modern key to fight against the cancer. The apoptosis is the self destruction of cells, part of the homeostasis, which regulates the cell developement. In several cancers, the over-expression of anti-apoptotic proteins, as Bcl-xL and Mcl-1 parts of the Bcl-2 proteins family, inhibate this naturel process. This phenomenum induce the tumoral cells developement and the chemotherapy’s resistance. In order to find new compounds which can regulate the apoptosis, our group in the Institut de Chimie des Substances Naturelles has screened different tropical plants on these targets. A Malaysian plant, Meiogynine Cylindrocarpa, was selected and the phyotchemist work on this plant gave us a new sesquiterpen , the meiogynin A (Ki = 10.7 M on Bcl-xL). Its total synthesis was realised in our laboratory in order to determine its absolute configuration and find the first structure activity relation. One of the synthetised diastereoisomers has presented a better affinity toward the protein. In order to precise these first structure activity relations, the modulation of the meiogynin A was initiated. The synthesis of the acid dienophiles was optimised, the main compounds are the precursors of the active decalins. New triene was also obtained in order to modulate the South Part of the meiogynin A. Thanks to a Diels-Alder reaction, these precursors were combined in order to form new analogues of the meiogynin A. All these compounds were biologically tested (in vitro et ex vivo). Experiments of molecular docking and 2D NMR were also realised
ANDRIAMANANTENA, RICHARD. "Trifluoromethylphenols : chimie et pharmacomodulation." Aix-Marseille 2, 1991. http://www.theses.fr/1991AIX22952.
Full textAmrane, Dyhia. "Pharmacomodulation d'hétérocycles α-trichlorométhylés ciblant l'apicoplaste chez P. falciparum." Electronic Thesis or Diss., Aix-Marseille, 2021. http://www.theses.fr/2021AIXM0379.
Full textMalaria remains the leading cause of death among parasitic infections worldwide. Currently, there are major concerns about the spread of resistance to artemisinin derivatives that are the basis of first-line antimalarial treatment. Therefore, there is an urgent need to develop new antiplasmodial molecules with a novel mechanism of action. For this purpose, our laboratory has previously described the synthesis and biological activities of a chemical library of α-trichloromethylated azaheterocycles including a hit molecule in the quinazoline series which presents the best biological profile.The first part of this work focused on 4-carboxamide quinazoline pharmacomodulation. In order to complete the SARs, scaffold hopping strategies allowed us to obtain new compounds in the quinoxaline and phthalazine series. By structural simplification, new compounds in the pyrimidine, pyridazine and pyrazine series were obtained. Finally, in order to explore the benzene part of the quinazoline and quinoxaline rings, new thienopyrimidine and pyrido[2,3-b]pyrazine derivatives were also synthesized. More than 110 new original molecules were obtained, among them several new hit molecules were obtained. The physicochemical and in vitro pharmacokinetic properties were determined in order to initiate the study of their in vivo activity on Plasmodium berghei. In addition, in order to elucidate the mechanism of action of these compounds, which differs from those of commercial antimalarials, we have recently identified by immunofluorescence that these molecules target the apicoplast of P. falciparum, an organelle essential to parasite survival
Delahousse, Julia. "De l’ifosfamide au géranyloxy-ifosfamide : pharmacomodulation pour cibler et moduler l’immunité." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS535.
Full textIfosfamide (IFO) is an alkylating agent of the DNA from Oxazaphosphorine family, widely used in various chemotherapy protocols. However, its clinical use is limited due to nephrotoxicity and neurotoxicity related to metabolites such as chloroacetaldehyde. Indeed, IFO is a prodrug characterized by complex pharmacokinetic profile with a minority activating metabolic pathway and a majority toxicogenic pathway. Chemical pharmacomodulation is one of the strategies proposed to bypass the toxicogenic pathway and thus improve its clinical use. IFO analogues (geranyloxy-, farnesyloxy-, squalenyloxy-, squalenyloxy-IFO), able to self-assembly, have been developed and pharmacological studies have demonstrated the proof of concept for the pre-activation of IFO. Galenic optimizations have been tested for pre-clinical and clinical application. In addition, due to the chemical similarity of IFO and cyclophosphamide, immunomodulation studies have been conducted to investigate the immunomodulatory properties of IFO and geranyloxy-IFO with the hope of new perspectives in the use of these compounds in combination with immunotherapy
Book chapters on the topic "Pharmacomodulations"
Tawansy, Khaled, Anand Muthiah, and Anika Muthiah. "Pharmacomodulation in the Treatment of Retinopathy of Prematurity." In Retinopathy of Prematurity, 79–94. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-52190-9_8.
Full textBourguet, Erika, William Hornebeck, Janos Sapi, Alain Jean-Paul, and Gautier Moroy. "Pharmacomodulation of Broad Spectrum Matrix Metalloproteinase Inhibitors Towards Regulation of Gelatinases." In Enzyme Inhibition and Bioapplications. InTech, 2012. http://dx.doi.org/10.5772/35412.
Full textConference papers on the topic "Pharmacomodulations"
Omene, CO, J. Wu, M. Kalac, OA O'Connor, and K. Frenkel. "Abstract P6-14-07: Epigenetic Pharmacomodulation of Therapeutic Targets in Breast Cancer with a Naturopathic Formulation of Propolis, a Honeybee Product." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-14-07.
Full text